State of Peptides — Q1 2026 — VialBase Guides
Quarterly report covering the peptide research landscape: regulatory shifts, compound spotlights, research developments, vendor trends, and market outlook for Q1 2026.
Report period: January — March 2026 Published: April 14, 2026 Edition: Inaugural issue
This is the first quarterly State of Peptides report from VialBase. Each edition covers the regulatory landscape, notable research developments, market trends, and emerging compounds. The goal is to provide a factual, well-sourced overview of the peptide research space — no hype, no speculation beyond what the data supports.
Executive Summary
Q1 2026 was defined by three forces: continued FDA regulatory tightening on compounded peptides, accelerating GLP-1/GIP/glucagon agonist clinical data, and growing mainstream interest in longevity-adjacent peptides. Search volume for peptide-related terms grew 18% year-over-year across the compounds tracked by VialBase.
Key developments:
- Regulatory: FDA’s Category 2 reclassification of BPC-157 under the 503A framework created supply uncertainty. New guidance on GLP-1 compounding practices signaled tighter enforcement ahead.
- Research: Retatrutide Phase 3 data emerged as the most significant clinical development. MOTS-c human pilot studies showed promise in metabolic health.
- Market: Tirzepatide overtook semaglutide in search volume growth (+34% YoY vs +22%). Bioregulator peptides gained traction in the longevity community.
1. Regulatory Landscape
FDA Actions
BPC-157 — Category 2 Reclassification
The FDA’s February 2026 reclassification of BPC-157 from Category 1 to Category 2 under the 503A bulk drug substance framework marked the most significant regulatory action of the quarter. Category 2 designation means the compound is considered “demonstrably difficult to compound” — not banned, but subject to heightened requirements for compounding pharmacies.
Impact: Reduced availability from 503A compounding pharmacies. Research-grade supply channels remain unaffected, but the move signals increasing regulatory scrutiny of peptides with large consumer demand and limited clinical trial data.
GLP-1 Compounding Guidance
The FDA issued updated guidance on GLP-1 receptor agonist compounding in March 2026. The guidance clarified that compounded semaglutide and tirzepatide are permissible only during documented drug shortages, with stricter verification requirements for compounding pharmacies.
Context: The branded GLP-1 shortage that enabled widespread compounding through 2024-2025 showed signs of easing by end of Q1 2026. If supply normalizes, compounding authorization may narrow.
State-Level Developments
Several states introduced peptide-related legislation in Q1:
- Florida: Proposed regulation of peptide clinics under telehealth oversight rules
- Texas: Continued permissive stance on peptide research compounds
- New York: Introduced labeling requirements for compounding pharmacies selling peptide products
WADA & Anti-Doping
No new peptide additions to the WADA Prohibited List in Q1 2026. BPC-157, TB-500, GH secretagogues, and IGF-1 variants remain prohibited under S0 (non-approved substances) and S2 (peptide hormones). Athletes should assume all research peptides are prohibited unless explicitly cleared.
2. Compound Spotlights
Retatrutide — The Triple Agonist Emerges
What happened: Phase 3 clinical trial data for retatrutide (GLP-1/GIP/glucagon triple agonist) showed unprecedented weight loss efficacy — up to 24% body weight reduction at 48 weeks in the highest dose arm. This exceeds both semaglutide (~15%) and tirzepatide (~21%) at comparable timepoints.
Why it matters: The glucagon component differentiates retatrutide from existing GLP-1/GIP agonists. Glucagon receptor activation increases energy expenditure and hepatic fat mobilization. Early data suggests superior efficacy for non-alcoholic fatty liver disease (NAFLD) compared to GLP-1-only compounds.
Watch for Q2: Phase 3 cardiovascular outcomes data expected. If MACE reduction matches or exceeds semaglutide’s SELECT trial results, retatrutide could define the next generation of metabolic therapeutics.
MOTS-c — From Mitochondria to Clinic
What happened: A 12-week human pilot study published in Cell Metabolism demonstrated that subcutaneous MOTS-c (10 mg/week) improved insulin sensitivity by 18% and reduced visceral fat by 7% in obese, insulin-resistant subjects. This is the first controlled human data beyond case reports.
Why it matters: MOTS-c is a mitochondrial-derived peptide — endogenously produced by the body. The human data validates the preclinical work showing AMPK activation and metabolic improvement. If replicated in larger trials, MOTS-c represents a novel mechanism distinct from GLP-1 agonists.
Limitations: Small sample (n=42), single-site study, no long-term follow-up. Dose-response relationship not established. Replication is needed before drawing strong conclusions.
Thymosin-Alpha-1 — Post-Pandemic Immune Modulation
What happened: A meta-analysis of thymosin-alpha-1 in immunocompromised patients (n=2,800 across 14 RCTs) confirmed statistically significant improvements in T-cell counts and infection rates vs. standard of care. The analysis included post-COVID immune reconstitution studies.
Why it matters: Thymosin-alpha-1 has the strongest clinical evidence base of any immune-modulating peptide. The meta-analysis moves it closer to potential regulatory re-engagement (it was previously FDA-approved under the brand name Zadaxin before voluntary market withdrawal).
Epithalon — Telomere Research Update
What happened: A Russian research group published a 3-year follow-up study on epithalon (10 mg/day x 10 days, cycled biannually) showing sustained telomere length maintenance in elderly subjects (n=60, ages 65-80) vs. controls who showed expected age-related telomere attrition.
Why it matters: This is the longest follow-up on epithalon in humans. The data is consistent with the proposed mechanism of telomerase activation via pineal peptide signaling. Limitations include the unblinded design and single research group producing most epithalon literature.
NAD+ — IV vs. Precursor Debate
What happened: A comparative study (n=120) measured intracellular NAD+ levels after 8 weeks of IV NAD+ (500 mg biweekly) vs. NMN (1g/day oral) vs. NR (1g/day oral). IV NAD+ produced 40% higher peak intracellular NAD+ levels, but NMN achieved 85% of the IV effect by week 8.
Why it matters: The cost-benefit of IV NAD+ ($500-1500/session) vs. oral precursors ($1-3/day) is a persistent question. This data suggests oral NMN approaches IV efficacy for sustained supplementation, though IV remains superior for acute repletion.
3. Research Roundup
Notable Publications — Q1 2026
| Compound | Finding | Journal | Significance |
|---|---|---|---|
| BPC-157 | Demonstrated neuroprotective effects in traumatic brain injury model via VEGF upregulation | Neuropeptides | Expands research areas beyond gut/musculoskeletal |
| GHK-Cu | Identified novel anti-fibrotic mechanism via TGF-beta pathway modulation | Journal of Investigative Dermatology | Supports wound healing and anti-scarring applications |
| Semaglutide | FLOW trial 3-year follow-up confirmed sustained kidney protection in T2D | NEJM | First GLP-1 with strong renal outcome data |
| Cerebrolysin | Phase 3 data in vascular dementia showed cognitive stabilization at 12 months | Alzheimer’s & Dementia | Largest neuropeptide dementia trial to date |
| SS-31 (Elamipretide) | Phase 2b in Barth syndrome showed sustained improvement in 6-min walk test | Circulation | Mitochondrial peptide therapeutic advancing |
| Kisspeptin | Demonstrated ability to restore LH pulsatility in hypothalamic amenorrhea | Lancet Diabetes & Endocrinology | Clinical validation of HPG axis restoration |
Preprint Watch
- Foxo4-DRI: First-in-human dose escalation study registered (NCT-pending) — senolytic peptide entering clinical development
- DSIP: Systematic review of sleep architecture effects across 8 preclinical models — consistent REM enhancement observed
- 5-Amino-1MQ: In vivo NNMT inhibition confirmed in adipose tissue biopsies — mechanism validation
4. Market & Vendor Landscape
Search Volume Trends (Q1 2026 vs. Q1 2025)
| Compound | Monthly Searches | YoY Change | Trend |
|---|---|---|---|
| Semaglutide | 2,400,000 | +22% | Mainstream awareness saturation approaching |
| Tirzepatide | 1,100,000 | +34% | Fastest-growing GLP-1; Zepbound brand awareness |
| BPC-157 | 165,000 | +12% | Regulatory news drove awareness spike |
| MK-677 | 110,000 | +8% | Steady — oral GH secretagogue audience is established |
| TB-500 | 74,000 | +15% | Healing stack interest growing |
| Retatrutide | 89,000 | +340% | From niche to mainstream as Phase 3 data dropped |
| NAD+ | 201,000 | +19% | Longevity market continuing to expand |
| Epithalon | 33,000 | +25% | Telomere/longevity community driving growth |
| MOTS-c | 12,000 | +180% | Human data catalyzed surge from low base |
| Thymosin-Alpha-1 | 18,000 | +42% | Post-pandemic immune resilience interest |
Supply Chain Notes
- GLP-1 agonists: Compounding supply stabilizing as branded production increases. Expect tighter FDA enforcement on compounders if shortage designation is lifted.
- BPC-157: Some 503A pharmacy supply disruption due to Category 2 reclassification. Research-grade channels stable.
- Bioregulator peptides (Khavinson): Primarily sourced from Eastern European manufacturers. Supply chains remain niche but reliable for established vendors.
- Raw peptide manufacturing: Chinese API manufacturers continue to dominate raw material supply. Quality variance remains the primary concern — certificate of analysis (COA) verification and third-party testing are essential.
5. Community & Emerging Trends
Trend 1: The Longevity Stack
Community interest in multi-peptide longevity protocols is growing. The most discussed combination in Q1:
- Epithalon (telomere maintenance) + NAD+ (cellular energy) + MOTS-c (metabolic optimization) + Thymosin-Alpha-1 (immune resilience)
Notably, this stack focuses on different biological axes rather than redundant mechanisms — a maturation from the earlier “more is better” stacking approach.
Trend 2: Post-GLP-1 Recovery Protocols
As more people cycle off semaglutide/tirzepatide, community discussion has shifted to weight regain prevention. Emerging protocols combine:
- BPC-157 (gut healing post-GLP-1 GI side effects)
- MOTS-c (metabolic rate maintenance)
- Ipamorelin (GH-axis support for body composition)
Trend 3: Cognitive Performance Stacks
Nootropic peptide interest grew 28% in Q1, driven by:
- Semax + Selank (established combination for focus + anxiety reduction)
- Cerebrolysin (gaining traction after vascular dementia data)
- Dihexa (controversial but discussed frequently in biohacker communities)
Trend 4: Bioregulator Peptides Go Mainstream
Khavinson bioregulator peptides — previously niche even within the peptide community — saw 60% aggregate search volume growth in Q1 2026. Key drivers:
- Podcasts and substacks covering longevity medicine
- Low risk profile appeals to peptide newcomers
- Targeted organ support concept is easy to understand and communicate
6. Outlook — What to Watch in Q2 2026
- Retatrutide Phase 3 cardiovascular data — If MACE reduction is confirmed, expect a regulatory fast-track and massive market impact.
- FDA GLP-1 shortage status update — If shortage designation is lifted, compounding will be restricted, affecting millions of current users.
- BPC-157 Category 2 enforcement — Watch for FDA warning letters to compounding pharmacies. Will signal enforcement posture.
- MOTS-c replication studies — At least two independent groups have registered trials. Confirmation of the pilot data would be significant.
- Foxo4-DRI first-in-human results — If the dose escalation study proceeds as registered, preliminary safety data could appear late Q2.
- Oral semaglutide formulation advances — Rybelsus optimization and competing oral GLP-1 formulations could shift the administration landscape.
Methodology
This report draws on: PubMed publications (January-March 2026), FDA.gov regulatory actions, ClinicalTrials.gov registrations, Google Trends search volume data, and the VialBase compound database. Search volume estimates are derived from SEMRush and Google Keyword Planner. Market trend observations incorporate VialBase site analytics and community forum analysis.
This report does not constitute investment, medical, or legal advice. It is an informational summary of publicly available data.
Next edition: State of Peptides — Q2 2026 (expected publication: July 2026)